SynthesisFrontiers in cardiovascular medicine2025
Single arm meta-analysis of the J-Valve system for aortic regurgitation in Chinese populations.
Synthesis in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transcatheter Aortic Valve Implantation for Pure Aortic Regurgitation.Journal of clinical medicine · 2026Review
- The First JenaValve Trilogy System Transcatheter Aortic Valve Replacement for Pure Severe Native Aortic Valve Regurgitation in Taiwan: A Case Report.Acta Cardiologica Sinica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This meta-analysis aimed to evaluate the efficacy and safety of J-valve in patients with Aortic regurgitation (AR). Methods: PubMed, Embase, the Cochrane Library, and Web of Science databases were searched from inception to November 2024. Primary outcome included Procedural Success, and secondary outcome included In-Hospital Mortality, 30-Day Mortality, One-Year All-Cause Mortality, Stroke Incidence and Complications. The risk of bias was assessed by subgroup analysis, sensitivity analysis, and publication bias, including funnel plot, Egger's test, and Begg's test. Results: A total of 9 studies involving 552 patients were included in this meta-analysis. The results indicated a surgical success rate of 96% (95% CI: 0.94-0.99). The in-hospital mortality rate was 3% (95% CI: 0.01-0.04), the 30-day mortality rate was 3% (95% CI: 0.01-0.05), and the 1-year all-cause mortality rate was 6% (95% CI: 0.04-0.08). Additionally, the incidence of stroke was 2% (95% CI: 0.01-0.03), and the incidence of other complications was 22% (95% CI: 0.16-0.28). Conclusions: This meta-analysis indicates that the J-Valve prosthesis exhibits favorable short-term efficacy in patients with severe aortic regurgitation (AR); however, a significant incidence of complications persists. A thorough risk assessment is crucial when determining the appropriate treatment strategy. Furthermore, postoperative follow-up duration should be extended to monitor patient outcomes effectively. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024552406, identifier CRD42024552406.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.